Johnson & Johnson has announced new long-term 52-week data from the phase 3 Iconic-advance 1 and 2 and Iconic-lead studies, which assessed the efficacy and safety of Icotyde™ (icotrokinra) in the treatment of patients with moderate-to-severe plaque psoriasis (PsO).
Icotyde is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.
Icotyde achieved high levels of complete skin clearance up to week 52 with no new safety signals, including:
- In the Icotyde treatment arms, rates of completely clear skin (PASI 100) increased from 41% to 49% and 33% to 48% from week 24 to week 52 in Advance 1 and 2, respectively.
- Patients who switched from placebo to Icotyde at week 16 achieved similar rates of complete skin clearance by week 52 (50% and 43% in Advance 1 and 2, respectively) as those who were treated with Icotyde for the full 52 weeks.
- The Icotyde adverse event profile through week 52 was consistent with that observed through week 16 and 24, and no new safety signal was identified through week 52. Icotyde overall adverse event and infection rates were lower than deucravacitinib through week 24.
Icotyde demonstrated sustained skin clearance and a favourable safety profile in adolescents through week 52 with no new safety signals identified in the Iconic-lead study.
